Clinical Trial Update: Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating safety, PK/PD, and clinical activity of KT-413 in adults with relapsed or refractory B-cell non-Hodgkin lymphoma, including diff…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• KT-413

Snippet

Sponsor: Kymera Therapeutics, Inc. | Conditions: Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma | Phase 1 | Status: COMPLETED